Search
Thioridazine
go.drugbank.com/drugs/DB00679ApprovedWithdrawnA phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. … (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
Synonyms: 3-Methylmercapto-N-(2'-(N-methyl-2-piperidyl)ethyl)phenothiazine, 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazineSulfoxone
go.drugbank.com/drugs/DB01145ApprovedSulfoxone is a water-soluble sulfone used as an antileprosy drug. It has been used with limited success in the treatment of dermatitis herpetiformis.
Levomethadone
go.drugbank.com/drugs/DB13515InvestigationalCategories: Drugs Used in Opioid Dependence, Drugs Used in Addictive DisordersGepotidacin
go.drugbank.com/drugs/DB12134ApprovedInvestigational[L52680] In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. … [L52680,L52685] In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea. [L54803]
Oxogluric acid
go.drugbank.com/drugs/DB08845InvestigationalNutraceuticalOxogluric acid (α-Ketoglutarate) is not approved for any indication in the world but is an investigational drug in the United States. … ammonia by oxogluric acid in hemodialysis patients.
Butorphanol
go.drugbank.com/drugs/DB00611ApprovedIllicitVet approvedIt is used in the management of severe pain.
Synonyms: (−)-N-cyclobutylmethyl-3,14-dihydroxymorphinanAminosalicylic acid
go.drugbank.com/drugs/DB00233ApprovedInvestigationalAn antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.
Asfotase alfa
go.drugbank.com/drugs/DB09105ApprovedInvestigationalAsfotase alfa is a first-in-class bone-targeted enzyme replacement therapy designed to address the underlying cause of hypophosphatasia (HPP)—deficient alkaline phosphatase (ALP). … Asfotase alfa was first approved by Pharmaceuticals and Medicals Devices Agency of Japan (PMDA) on July 3, 2015, then approved by the European Medicine Agency (EMA) on August 28, 2015, and was approved